The present invention is directed to pharmaceutical combinations for treating hepatitis B virus (HBV) infection comprising administering at least two, preferably two or three, different HBV therapeutics. In particular, the present invention relates to pharmaceutical combinations comprising an RNAi oligonucleotide targeting HBV and an anti-PDL1 antisense oligonucleotide.
The present invention is directed to (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, wherein the patient suffering from said cancer was previously under treatment with a different BRAF inhibitor.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention relates to novel compounds having the general formula (Ic) wherein R1, R2, R3, R8, R9, RX, A1, A2, W and n are as described herein, composition including the compounds and methods of using the compounds.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
4.
METHOD AND SYSTEM FOR IMPROVED OPTICAL ANALYTE MEASUREMENTS
A method for measuring an analyte includes identifying a test strip in a video stream generated by a camera based on at least one registration mark associated with the test strip depicted in the video stream, identifying application of a fluid dose to a deposit site formed on the test strip based on the video stream, activating a timer in response to the identification of the application of the fluid dose, generating at least one optical measurement of a reagent located at a measurement site on the test strip, and generating a measurement of an analyte in the fluid dose based on the at least one optical measurement of the reagent only in response to the at least one optical measurement being generated after a predetermined minimum time period has elapsed and prior to a predetermined maximum time period elapsing subsequent to the activating of the timer.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
5.
SYSTEM AND METHOD FOR AUTOMATED OPTICAL ANALYTE MEASUREMENTS VIA WEARABLE SMART DEVICES
Systems and methods for measuring an analyte include devices configured to perform an analyte testing operation. The devices include a wearable electronic device and a remote device operatively connected to each other and each having a processor, the processors cooperating with each other in the execution of program instructions to measure an analyte. The wearable electronic device includes a camera configured to generate a video stream, which is analyzed to identify missing test components, to identify the application of a body fluid on a test strip where the sample undergoes changes in one or more optical properties, the image of which is analyzed to determine a level of the analyte. The wearable electronic device further includes a head-up display (HUD) for providing output messages to the user relating to the performance and status of the analyte testing operation.
It is disclosed crystalline forms of (R) -N- (4- ( [1, 2, 4] triazolo [1, 5-c]pyrimidin-7-yloxy) -3-methylphenyl) -5- ( (3, 3-difluoro-1-methylpiperidin-4-yl) oxy) -6-methoxyquinazolin-4-amine, methods for the preparation thereof, pharmaceutical compositions comprising one or more of the crystalline forms as an active ingredient, and use of the crystalline forms in the treatment of hyperproliferative diseases.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Systems and methods for measuring an analyte include devices configured to perform an analyte testing operation. The devices include a wearable electronic device and a remote device operatively connected to each other and each having a processor, the processors cooperating with each other in the execution of program instructions configured to direct the devices in the performance of the analyte testing operation. The wearable electronic device includes a camera configured to generate a video stream and one or more images relating to a user removing a test strip from a vial, producing a bodily fluid sample, and applying the sample to a deposit site of the test strip where the sample undergoes changes in one or more optical properties, the image of which is analyzed to determine a level of the analyte. The wearable electronic device further includes a head-up display (HUD) for providing output messages to the user relating to the performance and status of the analyte testing operation.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
8.
ENHANCED METHOD FOR THE DETERMINATION OF AN ANALYTE CONCENTRATION IN BODILY FLUID
The present invention relates to an analytical method for determining a concentration of an analyte in a bodily fluid by using a mobile device having at least one camera, at least one lidar sensor, at least one processor, and at least one display, wherein the at least one camera and the at least one lidar sensor comprise an at least partially overlapping field of view, the method comprising the following steps: a) providing at least one object, the at least one object being selected from the list comprising: an optical test element having a reagent test region, a color reference card having a reagent test region, a color reference card adapted to be associated with an optical test element having a reagent test region; wherein the reagent test region is adapted for application of a sample of the bodily fluid, and wherein the reagent test region is adapted to undergo, at least partially, a color formation reaction when the sample of the bodily fluid is applied to the reagent test region; b1) prompting, by the display, a user to apply a drop of the bodily fluid to the reagent test region and/or prompting, by the display, a user to confirm application of a drop of the bodily fluid to the reagent test region; b2) prompting, by the display, the user to provide the at least one object within the at least partially overlapping field of view of the at least one camera and the at least one lidar sensor; c) generating, by the processor, a lidar measurement data set at least for the object by receiving output data from the at least one lidar sensor, the lidar measurement data set representing a three-dimensional structure of at least a part of the object; d) comparing, by the processor, the lidar measurement data set from step c) to a pre-generated lidar data set for the object, the pre-generated lidar data set representing a three-dimensional structure of the entire object, thereby obtaining an item of information on a degree of congruence of the lidar measurement data set and the pre-generated lidar data set; and e1) if the item of information from step d) indicates a degree of congruence equal to or above a pre-determined minimum degree of congruence: capturing, by the at least one camera, a measurement image of at least a part of the reagent test region having the sample of the bodily fluid applied thereto, and determining the concentration of the analyte in the bodily fluid based at least on the measurement image captured; or e2) if the item of information from step d) indicates a degree of congruence below a pre-determined minimum degree of congruence: - at least temporarily not allowing the capturing, by the at least one camera, of a measurement image of at least a part of the reagent test region having the sample of the bodily fluid applied thereto; and/or - indicating, by the display, a warning to the user; and/or - indicating, by the display, instractions to the user to take some appropriate action in order to capture, by the at least one camera, a measurement image of at least a part of the reagent test region having the sample of the bodily fluid applied thereto.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01S 17/88 - Lidar systems, specially adapted for specific applications
The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
10.
BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR
The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61P 25/00 - Drugs for disorders of the nervous system
C07D 243/26 - Preparation from compounds already containing the benzodiazepine skeleton
A medical delivery device (1) comprises a barrel assembly (2) with a hollow interior (215) and a first thread arrangement (212), a rod assembly (3) with a second thread arrangement (312) and a plunger rod element (32) having a longitudinal axis and extending into the hollow interior (215) of the barrel assembly (2), and a dosage chamber (94) formed in the hollow interior (215) of the barrel assembly (2) with a variable volume limited by the plunger rod element (32) of the rod assembly (3). The barrel assembly (2) and the rod assembly (3) are rotatable relative to each other. The first thread arrangement (212) of the rod assembly (3) and the second thread arrangement (312) of the barrel assembly (2) engage such that rotation of the barrel assembly (2) and the rod assembly (3) relative to each other moves the rod assembly (3) along the longitudinal axis of its plunger rod assembly (3) causing the volume of the dosage chamber (94) to vary. The device (1) further comprises a rotation inhibiting formation (42) coupled to the barrel assembly (2) and the rod assembly. The rotation inhibiting formation (42) defines an extra rotation resistance affecting rotation of the barrel assembly (2) and the rod assembly (3) relative to each other.
The present invention relates to an analyte sensor comprising a substrate, a first conductive material, a second conductive material, a first layer and a second layer, wherein the first and the second layer, in-dependently of one another have a varying thickness along the length of the substrate and/or are located on the substrate as at least two fields separate from one another. The present invention further-more relates to a method for manufacturing the analyte sensor and an analyte sensor system comprising the analyte sensor.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase
13.
PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
The present invention relates to compounds of formula (I), (I), wherein R1 to R3, A, M, W and Q are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
15.
KIT FOR FORMING A MICROPLATE ASSEMBLY FOR ABSORBANCE MEASUREMENTS OF LIQUID SAMPLES
A kit for forming a microplate assembly for absorbance measurements of liquid samples comprises an upper plate (1) comprising at least one plurality of rods (12), each rod (12) having a flat rod bottom surface (121), a lower plate (2), and alignment guides for aligning the upper plate (1) and the lower plate (2) relative to each other as well as spacers for determining the distance of the upper plate (1) and the lower plate (2) relative to each other. The lower plate (2) comprises a plurality of wells (22), each having a flat well bottom surface (221). The alignment guides are configured and arranged such that each well (22) accommodates one rod (12) of each plurality of rods. The spacers comprise a plurality of threaded adjustment bolts (13a, 13b, 13c) which are arranged such that, when the upper plate (1) and the lower plate (2) are assembled to form the microplate assembly, each flat rod bottom surface (121) is arranged parallel to the corresponding flat well bottom surface (221) at a predetermined distance (43) in the range of 0.5 mm to 5 mm.
The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
A method of controlling auto white balance settings of a mobile device with a camera and preset auto white balance modes for performing a color based measurement comprising the steps of capturing an image of at least part of one or more gray fields of a color reference card, determining for a region of interest within the image a number of gray fields for which the color information for a first and a second color shows overexposure as a first and second overexposure-number, respectively, the first color relating to a smaller wavelength than the second color, and re-capturing the image with a warmer white balance mode if the first overexposure number is greater than the second overexposure number or re-capturing the image with a cooler white balance mode if the first overexposure number is smaller than the second overexposure number.
G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 21/29 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 21/84 - Systems specially adapted for particular applications
G09G 3/20 - Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix
G09G 5/02 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the way in which colour is displayed
18.
FACILITATING ADHERENCE TO TASKS DESIGNED TO MAINTAIN OR IMPROVE HEALTH
A user device (e.g., a mobile device) may determine a first notification visibility level for the user health-related event based on a context. The user device may receive data associated with the user health-related event. The user device may determine an adherence level for the user health-related event based on the data associated with the user health-related event. The user device may determine a second notification visibility level for the user health-related event based on comparison of the adherence level to a plurality of predefined adherence thresholds. The user device may communicate, using the second notification visibility level, a notification associated with the user health-related event via the user device upon detection of a triggering event. The user device may group, based on the context, one or more user health-related events into a notification group.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G08B 21/24 - Reminder alarms, e.g. anti-loss alarms
G16H 10/65 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
The invention relates to a system, a sensor and a method for measuring an analyte concentration using an electrochemical analyte sensor, the analyte sensor comprising a first electrode and a second electrode, the first electrode being configured to react with the analyte for generating an electrical signal, wherein the method comprises: applying (201) a modulated voltage signal between the first electrode and the second electrode, determining (202) a current signal in response to the applied modulated voltage signal, determining (203) an electric potential working point of the analyte sensor based on the determined current signal, operating (204) the analyte sensor at the determined electric potential working point, and measuring (205) the analyte concentration based on the electrical signal generated by the first electrode.
This invention relates to methods and compositions for use in treating cancer in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1 ) and lymphocyte activation gene-3 (LAG3).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention generally relates to heterodimeric Fc domain antibodies as well as to combination with antigen binding receptors capable of specific binding to such antibodies comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with such antigen binding receptor and kits comprising the transduced T cells and tumor targeting antibodies comprising such heterodimeric Fc domains.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
22.
ANALYTE SENSOR AND METHOD FOR MANUFACTURING AN ANALYTE SENSOR
An analyte sensor comprises a substrate, at least one working electrode, at least one second electrode and a membrane, wherein the membrane is located on top of the second electrode, and the second electrode has at least one first silver layer and at least one second silver layer which partially overlap with one another and have different compositions, i.e. silver percentages. The sensor includes at least one exposed area of the first silver layer disposed on the exterior of the sensor to provide for direct contact with body fluid when implanted. The disclosure further relates to a process for manufacturing an analyte sensor.
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase
23.
SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO
A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective Pt/V/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.
This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (ORC) (e.g., metastatic ORC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic ORC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIG IT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1 ) and lymphocyte activation gene-3 (LAGS), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CDS (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to intermediates and processes useful for preparing 1-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide and salts thereof. The present invention further relates to 1-ethyl-N-((1,2,3,5,6,7- hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide and salts thereof when prepared by such processes and to associated pharmaceutical compositions and uses for the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
The present invention relates to a crystalline potassium salt of 1-ethyl-N-((1,2,3,5,6,7- hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical diseases, disorders and conditions, most especially by NLRP3 inhibition.
The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention provides solid forms of (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide and solvates thereof, as well as therapeutic uses and processes to manufacture the new solid forms.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present invention is directed to a combination of the BRAF inhibitor N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy- phenyl]-3-fluoro-pyrrolidine-l-sulfonamide or a pharmaceutically acceptable salt or solvate thereof with a PD-1 axis binding antagonist, and to the use of the combination as a medicament, in particular for the therapeutic and/or prophylactic treatment of cancer.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to oligonucleotides that upregulate or restore the expression of progranulin in cells by targeting the promoter region of the progranulin gene. The invention further relates to pharmaceutical compositions and methods for the treatment of diseases associated with progranulin, specifically progranulin haploinsufficiency and neurological disorders.
The invention relates to novel compounds having the general formula Ib wherein R1, R2, R3, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The invention relates to novel compounds having the general formula Ib Ib wherein R1, R2, R3, R4, R5, and Z are as described herein, composition including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A method to determine a subject's blood glucose level non-invasively by analyzing an exhaled breath or another gaseous emanation from the subject, comprising non-invasively detecting an amount of at least one volatile organic marker in the subject's exhaled breath or the subject's other gaseous emanation as marker data and determining the subject's blood glucose level based on the marker data, wherein the volatile organic marker is selected from a group of markers for which the amount of the volatile organic marker is negatively correlated to the blood glucose level. The volatile organic marker is one of indole (C8H7N), a partly saturated derivative of indole, a fully saturated derivative of indole and a true fraction of indole.
An analyte sensor (110) for determining at least one analyte and a method (140) for producing an analyte sensor (110) are disclosed. The analyte sensor (110) comprises: - a substrate (112); - a working electrode (118) and a conductive layer (122, 124) located on different sites on the substrate (112); - a silver comprising layer (126) partially covering the conductive layer (124); and - a protective layer (128) covering - the silver comprising layer (126) fully apart from at least one area (130) accessible to at least one body fluid comprising the at least one analyte; and - a portion of the conductive layer (124). The analyte sensor (110) as proposed herein significantly reduces noise during measurements. The method (140) which can be performed in an easier manner compared to producing prior art analyte sensors allows considerably higher tolerances during the producing of the analyte sensor (110).
Methods for preparing the Bruton's Tyrosine Kinase ("BTK") inhibitor compound 2-{3'-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4']bipyridinyl-2'-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
37.
METHOD FOR DETERMINING A RELIABILITY OF AN ANALYTE SENSOR
A method for determining a reliability of an analyte sensor (110) is proposed. The analyte sensor (110) is an in vivo sensor. The method comprises the steps: a) measuring at least one first temperature dependent signal; b) measuring at least one second temperature dependent signal which is different from the first temperature dependent signal and which is related to a current flow in the analyte sensor (110); c) correlating the first temperature dependent signal and the second temperature dependent signal for determining the reliability of the analyte sensor (110).
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/1495 - Calibrating or testing in vivo probes
38.
DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATE
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A method for generating activity recommendations in a diabetes treatment plan includes receiving physiological data, preferences, and suggested activities for a person with diabetes (PwD), generating physiological profiles for the PwD, providing the physiological profiles to a virtual physiological model, receiving projections from a virtual physiological model, generating weighted values based on the suggested activities and preference data, each weighted value corresponding to a likelihood of the PwD adhering to a suggested activity, ranking each activity based on the estimated change in the physiological characteristic of a projection associated with the activity relative to a baseline physiological projection and scaled by the weighted value corresponding to each activity, and generating an output including a predetermined number of suggested activities ordered based on the ranking of activities that provide a greatest change in the physiological characteristic given the likelihood of the PwD adhering to the suggested activities.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
40.
DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY
The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
The invention provides new heterocyclic compounds having the general formula (I), wherein A, B, X, and R1 to R7 are as described herein, compositions including thecompounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.
Method and means for postprandial blood glucose level prediction The invention relates to a method (100) for predicting blood glucose levels, in particular for postprandial blood glucose level prediction, the method being computer-implemented and comprising: receiving (101) a first medical data set of a patient covering a time range, said first medical data set comprising glucose data and further other medical data of said patient, extracting (102) a second medical data set from said first medical data set, wherein the second medical data set is a subset of the first medical data set and wherein the extracting comprises at least one of: identifying (103) duplicates in the first medical data set and removing identified duplicates, identifying (104) data values that lie above a predefined maximum threshold data value or identifying (105) data values that lie below a predefined minimum threshold data value and removing data associated to said identified data values, identifying (106) data values that differ from predetermined expected data values by more than a predetermined amount and removing data associated to said identified data values, identifying (107) incomplete data for which data values are missing and removing identified incomplete data, identifying (108) at least one predetermined time-dependent data pattern and removing data associated to said identified time-dependent data pattern, providing (109) the extracted second medical data set as input to a blood glucose level prediction model, and predicting (110) future blood glucose levels of the patient using the output of the blood glucose level prediction model based on the second medical data set.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
44.
MACHINE LEARNING-BASED PREDICTION OF TREATMENT REQUIREMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
A method and system for managing a treatment for a subject diagnosed with neovascular age-related macular degeneration (nAMD). Spectral domain optical coherence tomography (SD-OCT) imaging data of a retina of the subject is received. Retinal feature data is extracted for a plurality of retinal features using the SD-OCT imaging data, the plurality of retinal features being associated with at least one of a set of retinal fluids or a set of retinal layers. Input data formed using the retinal feature data for the plurality of retinal features is sent into a first machine learning model. A treatment level for an anti-vascular endothelial growth factor (anti-VEGF) treatment to be administered to the subject is predicted, via the first machine learning model, based on the input data.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
45.
PURIFICATION OF ANTIBODIES BY MIXED MODE CHROMATOGRAPHY
Herein is reported a method for producing or purifying an antibody using a mixed mode chromatography material that comprises ion exchange functional groups and hydrophobic interaction functional groups (MM HIC/IEX) operated in flowthrough mode, wherein the antibody is a hydrophilic antibody, and the antibody is applied in a solution comprising the antibody and an antichaotropic salt to the MM HIC/IEX chromatography material.
Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I), or a stereoisomer thereof: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and n are as defined herein; and compounds prepared by these processes.
C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
A method for screening a subject for the risk of chronic kidney disease (CKD) is provided, the method comprising: receiving marker data indicative for a plurality of marker parameters for a subject, such plurality of marker parameters indicating at least an age value, a time since diagnosis value indicative of a time since a diabetes diagnosis for the subject, a sample level of creatinine, an estimated glomerular filtration rate, a sample level of albumin, and a sample level of blood urea nitrogen; and determining a risk factor indicative of the risk of suffering CKD for the subject from the plurality of marker parameters. Further, a computer-implemented method for screening a subject for the risk of CKD is provided. Also, a system comprising a processor and a non-transitory memory storing a program causing the processor to perform the method for screening a subject for the risk of CKD is provided. In another aspect, a computer program product comprising instructions which, when the program is executed by a computer, cause the computer to carry out the method for screening a subject for the risk of CKD is provided.
The present disclosure provides methods for treating lupus nephritis in an individual that is greater than or equal to 12 years of age and less than 18 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a process for the preparation of 7-(4,7- diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2- a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
The invention relates to a compound of formula (I) wherein R1-R4 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
51.
COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti- CEA/anti-CD3 bispecific antibody.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure provides pharmaceutical compositions for treating or preventing myasthenia gravis comprising satralizumab as an active ingredient.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are novel biomarkers for identifying patients, with cancer, likely to benefit from treatment with an anti-CD25 agent. Also disclosed are methods using said biomarkers for making a treatment decision or monitoring treatment with an anti-CD25 agent as well as methods of treating a patient, with cancer, comprising administering an anti-CD25 agent based on prior use of the present biomarkers.
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 25/00 - Drugs for disorders of the nervous system
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A method for determining at least one membrane property of an analyte sensor (112) is pro-posed. The analyte sensor (112) comprises at least two measurement electrodes (114). At least one of the measurement electrodes (114) comprises at least one membrane element (122) having at least one membrane property. The method comprising the following steps: a) (134) generating at least one fast-transient voltage signal and applying the fast-transient voltage signal to the measurement electrodes (114) at an application time t0; b) (136) measuring a first response signal U1 at a first time t1 and a second response signal U2 at a second time t2 with t0 ? t1 ? t2, wherein the application time t0 precedes the first time t1 and the second time t2; c) (138) determining a response signal U0 at the application time t0 by evaluating the first response signal U1 and the second response signal U2; d) (140) determining the at least one membrane property by evaluating of the response signal U0 at the application time t0.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase
The invention relates to a method (100) for updating at least one medical practice software for displaying and analyzing blood glucose data on at least one computing device of a plurality of computing devices of a local network, the method comprising: determining (101), by a first computing device of said plurality of computing devices, what versions of the at least one medical software are installed on the computing devices of said plurality of computing devices; receiving (102), at a first computing device of said plurality of computing devices, at least one software patch, said software patch comprising at least one update for a version of the medical software installed on at least one computing device of said plurality of computing devices; identifying (103), by the first computing device, which of the at least one computing device of said plurality of computing devices has installed a version of the at least one software that requires an update comprised in said at least one software patch; transmitting (104), by the first computing device, a copy of the at least one software patch, to at least one computing device of said plurality of computing devices that has been identified as having installed a version of the at least one medical practice software that requires an update comprised in said at least one software patch; and installing (105) the at least one update from the software patch to update the medical practice software on at least one computing device identified by the first computing device.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
Herein is reported a method for the purification or production of a therapeutic polypeptide using the same depth filter multiple times, i.e. a depth filter which has been used before and has been regenerated. Reported herein is a method for purifying or producing a therapeutic polypeptide, characterized in that the method comprises the following steps: a) filtering an aqueous composition containing said therapeutic polypeptide and impurities through a depth filter, recovering the flow-through and thereby obtaining said purified therapeutic polypeptide, b) contacting said depth filter with a regeneration solution and thereby regenerating the depth filter, and c) repeating steps a) and b) one or more times.
The invention relates to a novel process for the production of a linear P-linked oligonucleotide which comprises the removal of the acid labile 5'hydroxy protecting group at the 5'- O oligonucleotide with a detritylation solution comprising acetonitrile. The process allows to produce oligonucleotides with low content of depurination and N-1 impurities.
C07H 1/00 - Processes for the preparation of sugar derivatives
B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
59.
INSERTION SYSTEM AND METHOD FOR INSERTING A MEDICAL DEVICE
An insertion system (110) is disclosed. The insertion system (110) comprises a medical device (112) and an insertion device (113) for inserting the medical device (112) into a body tissue of a user, the insertion device (113) comprising: i) an insertion component (118) configured for inserting the medical device (112) into the body tissue; ?) an insertion component retractor (120); iii) a cap (122); iv) a guide sleeve (124) and an insertion sleeve (128) guided therein; v) a locking sleeve (126) positioned in the insertion sleeve (128); and vi) an elastic member (130) positioned between the locking sleeve (126) and the insertion component retractor (120); wherein, for inserting the medical device (112), the cap (122), the insertion component retractor (120), the locking sleeve (126) and the insertion sleeve (128) are movable relative to the guide sleeve (124) from a distal position to a proximal position, wherein the insertion device (113) is separable from the medical device (112), wherein the insertion system (110) is configured such that a separation of the insertion device (113) from the medical device (112) releases a movement of the locking sleeve (126) from its proximal position to a further proximal position.
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using them in the treatment of cancer.
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention provides compounds of formula I or II: (I) wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Medical device efficiency detection methods and systems including a photoplethysmography (PPG) sensor device, a processor, a memory, and machine readable instructions that may cause the system to receive a notification at the PPG device from the medical device upon delivery of the therapy treatment, use the PPG device to search for a signal response of the user based on the notification within a period of time to generate a response signal indicative of therapy treatment delivery, and transmit an alert when the response signal is not generated in the period of time indicative of a failure to detect sufficient therapy treatment delivery. The instructions may cause the system to transmit an alert when signal measurements from the PPG device of an infusion site are not within a sufficient signal range to indicate the infusion site is insufficient for delivery of the therapy treatment by the medical device.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
63.
SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
197 ABSTRACT OF THE DISCLOSURE The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention comprises a process for the preparation of a chiral triol of formula (I) wherein, R1 is hydrogen or halogen by way of an asymmetric hydrogenation of a ketone compound of formula (IIa) wherein, R1 is hydrogen or halogen and R2 is C1-6-alkyl; with hydrogen in the presence of an iridium spiro-pyridylamidophosphine catalyst (Ir-SpiroPAP catalyst). The chiral triols of formula I are versatile building blocks for the preparation of various pharmaceutically active drug substances such as for instance for statins.
C07C 29/17 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds
C07C 33/26 - Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
The invention relates to combination therapies employing anti-PD1/anti-LAG3 bispecific antibody and a CD20 T cell-activating bispecific antibody, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates antibodies that bind to human HLA- G, multispecific antibodies thereof, their preparation, formulations and methods of using the same. In particular, specific variants of the antibody designated HLA-G-0090 are provided with mutations in the CDR1 of the variable region of the light chain (CDR-L1) which comprises a potential glycosylation site (NSS). Two particular variants showed improved binding properties, good expressability and stability, while showing no more N-glycosylation at the CDR-L1 of the light chain (so no Fab glycosylation could be detected). In one embodiment bispecific antibodies are disclosed comprising the variants for the HLA-G antibody and an antibody binding human CD3.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
PROCESS FOR THE PREPARATION 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3- AZABICYCLO[3.2.1]OCTAN-8-YL]-6,7-DIHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE
The present invention relates to a process for the preparation of a compound (I), (I); or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disease associated with the deposition of ß-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
69.
PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM
The present invention relates to a process for the preparation of a compound (I), and its solid form, which is a modulator of ?-secretase and may be useful for prophylaxis and treatment of a disease associated with the deposition of ß-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
70.
COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER
Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R2', R3, R4 and R5 are as described herein. The compound of formula (I) can be used as a medicament.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retaine IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH- dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH- dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
A user device (e.g., a mobile device) receives testing period data during a testing period. The user device determines that a portion of the data is missing based on an analysis of the received testing period data. The analysis of the received data includes an analysis of one or more blood glucose levels and an analysis of the dietary intake data, the medication data, and the activity data. The user device imputes the missing portion of the data with substitute data determined using predictive learning. The user device calculates a confidence level associated with the substitute data. The user device identifies, using the substitute data, a progression or a regression in a diabetic condition associated with the user.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
74.
METHOD FOR PREPARING A COUNTER/REFERENCE ELECTRODE
The present invention generally relates to a method for the preparation of an electrode and to an analyte sensor comprising the electrode as well as to the use of the analyte sensor for detecting at least one analyte in a sample. In particular, the invention relates to a method for the preparation of an electrode, the method comprising a partial reduction of Ag+ cations present in the electrode material.
The invention relates in particular to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined in the description and in the claims.
A method for the preparation of a working electrode comprises application of a sensing material in several steps. Further, an analyte sensor comprises the working electrode and is used for detecting at least one analyte in a sample.
The present invention generally relates to a flux-limiting polymer membrane for an analyte sensor and to an analyte sensor comprising a flux-limiting polymer membrane.
The present invention relates to a method for the preparation of a working electrode, the method comprising application of a sensing material in several steps. Further, the present invention relates to an analyte sensor comprising the working electrode as well as to the use of the analyte sensor for detecting at least one analyte in a sample.
The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to glycosylation patterns at the Fab portion of a monoclonal antibody and methods for the regulation during culture of a microorganism expressing a monoclonal antibody with regulated content of high mannose Fab glycoforms.
P36339 - 35 - Method for manufacturing at least one electrode of an analyte sensor Abstract A method for manufacturing at least one electrode (110) of an analyte sensor (112) is dis-5 closed. The method comprises the following steps: a) providing (116) a stencil (118), wherein the stencil (118) comprises a first stencil side (120), a second stencil side (122) and at least one through hole (124) reaching from the first stencil side (120) to the second stencil side (122), wherein at least one of the first stencil side (120) and the second stencil side (122) has first wetta-10 bility properties; b) providing (126) a substrate (128), wherein the substrate (128) comprises a first side (130) and a second side (134); c) applying (136) the stencil (118) to the first side (130) of the substrate (128); d) applying (138) a low viscosity composition (140) into the through hole (124) of 15 the stencil (118), wherein the low viscosity composition (140) has second wetta- bility properties opposing to the first wettability properties of the at least one of the first stencil side (120) and the second stencil side (122); e) drying (141) the low viscosity composition (140); f) obtaining (142) the at least one electrode (110). 20 (Figure 2A)
A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using enzyme electrodes, e.g. with immobilised oxidase
82.
COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHIBITORS
The present invention relates to combination therapies employing PD-1 axis binding antagonists and LRRK2 inhibitors and, and the use of these combination therapies for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
83.
A METHOD OF CONTROLLING AUTO-EXPOSURE SETTINGS OF A MOBILE DEVICE HAVING A CAMERA
A method of controlling auto-exposure settings of a mobile device having at least one camera is disclosed. The method comprises a) providing a color reference card (110) and an optical test strip (118) having a test field (120) having a sample applied thereto, o wherein the color reference card (110) comprises a plurality of different color reference fields (112) having known reference color values and one or more gray background fields (114) having defined gray values, b) setting an exposure metering area and determining auto-exposure settings based on the scene (126) in the set exposure metering area; o wherein the scene (126) in the set exposure metering area comprises at least part of the reagent test field (120) of the optical test strip (118) having the sample applied thereto, and at least part of the plurality of different color reference fields (112) and at least part of the one or more gray background fields (114) of the color reference card (110), c) capturing, by using the camera (120), at least one image comprising the scene (126) of step b) o wherein the determined auto-exposure settings of step b) are used. A method of determining the concentration of an analyte in a sample by using a mobile device is also disclosed.
Herein is reported a novel adenoviral VA RNA nucleic acid wherein the wild-type type 2 polymerase III promoter has been removed and an U6-snRNA promoter or an inducible promoter has been added.
A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican. A therapeutic molecule targeted to a tissue in a patient may comprise a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican that are bound to (i.e., pre-complexed with) hyaluronic acid. Methods of delivery for a therapeutic molecule targeted to a tissue in a patient comprise administering any therapeutic molecule described herein to the patient and allowing the therapeutic molecule to provide long-acting delivery of the therapeutically active agent to the target tissue.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican. A therapeutic molecule targeted to a tissue in a patient may comprise a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican that are bound to (i.e., pre-complexed with) hyaluronic acid. Methods of delivery for a therapeutic molecule targeted to a tissue in a patient comprise administering any therapeutic molecule described herein to the patient and allowing the therapeutic molecule to provide long-acting delivery of the therapeutically active agent to the target tissue.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
Herein are reported novel DNA constructs and methods using the same. The current invention uses a deliberate arrangement of non-productive/inactive promoters and genes on coding and template strands of DNA molecules, which are converted into their active form by the interaction with a site-specific recombinase. In more detail, the DNA element according to the current invention is non-functional with respect to the expression of the contained first and second genes. By being non-functional with respect to the expression of the first and second gene, the DNA element according to the invention can be integrated into genome of a cell without the risk that the comprised structural genes are expressed already directly after the integration. The genes are only expressed once a recombinase recognizing and functional with the recombination recognition sequences of the DNA element is activated or introduced into the cell. Thereby, a recombinase mediated cassette inversion (RMCI) between the first and second mutated recombinase recognition sequences in the genomically integrated DNA element of the invention is initiated. The RMCI results in an inversion of that part of the DNA element according to the invention that is located between the two mutant recombinase recognition sequences. Thereby the first promoter becomes operably linked to the first gene and the second promoter becomes operably linked to the second gene. Only thereafter, the first and second genes are transcribed and the respective encoded proteins are expressed. Thus, the DNA element according to the current invention is especially useful in the simultaneous activation of two genes within a cell.
A method of determining the concentration of at least one analyte in a bodily fluid by using a mobile device (112) is disclosed, the mobile device (112) having at least one camera (114) and at least one ambient light detector (122), the ambient light detector (122) comprising at least one of an ambient light sensor (124) and an additional camera (126), the method comprising: i. performing at least one ambient light check (178), the ambient light check (178) comprising: i.1 using the ambient light detector (122) for determining at least one item of ambient light information; and i.2 determining if at least one validity criterion on the item of ambient light information is fulfilled; ii. if the validity criterion is fulfilled, determining the concentration of the analyte in the bodily fluid by evaluating at least one image of at least a part of at least one reagent test region (118) of an optical test strip (116) having a sample of the bodily fluid applied thereto, the image being captured by the camera (114) of the mobile device (112). Further, a mobile device (112), a kit (110), a computer program and a computer-readable storage medium is disclosed.
Processes for preparing biheteroaryl compounds are provided, including the biheteroaryl compound 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine. Among other advantages, the processes provide for: the use of solvents that are relatively non-toxic and inexpensive; reduced usage of expensive precious metal catalysts; reaction temperature reduction in certain steps; the use of relatively non-toxic oxidation agents; the use of inexpensive transition metal catalysts; a reduction of molar ratios of certain reactants thereby improving process efficiency while reducing cost and waste; significantly higher reactant concentrations in certain steps; elimination of the need for multiple chromatographic purification steps; elimination of the need for certain extraction steps using organic solvent; and provide for higher yield and improved purity.
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
90.
INSERTION DEVICE AND METHOD FOR INSERTING A MEDICAL DEVICE
An insertion device (110) for inserting a medical device (112) into a body tissue of a user is disclosed. The insertion device (110) comprises: i) the medical device (112); ii) an insertion component (118) configured for inserting the medical device (112) into the body tissue; iii) an insertion component retractor (120); iv) a cap (122); v) a guide sleeve (124) comprising at least one ramp (126); and vi) an insertion sleeve (128); and vii) an elastic member (130); wherein, for inserting the medical device (112), the cap (122), the insertion component retractor (120) and the insertion sleeve (128) are movable relative to the guide sleeve (124) from a distal position (164) to a proximal position (166), wherein the ramp (126) of the guide sleeve (124) is configured to twist the insertion component retractor (120) relative to the guide sleeve (124) and the insertion sleeve (128) when the cap (122) is moved from its distal position (164) to its proximal position (166), wherein the cap (122) is movable from its proximal position (166) to its distal position (164), thereby the insertion component retractor (120) is moved from its proximal position (166) to its distal position (164). Further, a method for inserting a medical device (112) into a body tissue of a user is disclosed.
The invention relates to a method of manufacturing an in vivo analyte sensing device, which is adapted for detecting at least one analyte in a body fluid or tissue and an in vivo analyte sensing device obtainable by said manufacturing method. Further, the present invention relates to a method of manufacturing a sensor base plate and a sensor base plate obtainable by said manufacturing method. The sensor base plate may be used for the manufacture of an in vivo analyte sensing device.
The present invention relates to the prevention or mitigation of adverse effects related to T cell bispecific antibodies, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using a tyrosine kinase inhibitor such as dasatinib.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Herein is reported a method for generating a recombinant mammalian cell expressing a heterologous polypeptide and a method for producing a heterologous polypeptide using said recombinant mammalian cell, wherein in the recombinant cell the expression of at least the endogenous gene MYC has been reduced. It has been found that the knockout of at least the endogenous gene MYC in mammalian cells, e.g. such as CHO cells, improves recombinant productivity by the cells.
Some embodiments relate to methods, systems, uses, or software for generating a consensus sequence of a particular molecule. A set of sequences of the particular molecule can be accessed, each having been generated independently from other sequences in the set of sequences and each including an ordered set of bases. An alignment process may be performed using the set of sequences to generate an alignment result associating, for each base of the ordered sets of bases of the sets of sequences. The base may have a reference position. For each reference position of a set of reference positions, a feature vector for the reference position may be generated that represents each base from the ordered sets of bases aligned to the reference position. The feature vectors for the set of references positions may be processed using a machine learning model to generate the consensus sequence for the particular molecule.
The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61P 25/00 - Drugs for disorders of the nervous system
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to the combination therapy of specific PD-1- targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-Ll.
An apparatus (110), specifically a medical system (112), is disclosed, the apparatus (110) comprising: a. a medical device (114) which is at least partially insertable into a body tissue of a user; b. an insertion device (116) for at least partially inserting the medical device (114) into the body tissue; c. a housing (118); and d. a removable cap (120) connected to the housing (118), the removable cap (120) being configured for being removed from the housing (118) before insertion of the medical device (114), wherein the housing (118) and the removable cap (120), prior to removal of the removable cap (120), are connected via at least one flexible connection element (122), wherein the flexible connection element (122) is reversibly displaceable from a locking position (216) in which the removable cap (120) is secured to the housing (118) by the flexible connection element (122) into a releasing position (218) in which the removable cap (120) is released, wherein the flexible connection element (122), prior to use, is secured in the lock- ing position (216) by at least one frangible securing element (124). Further, a method for preparing the apparatus (110) for insertion of at least a part of the medical device (114) into the body tissue of the user and a method for at least partially inserting at least a part of the medical device (114) of the apparatus (110) into the body tissue of the user are disclosed.
The present disclosure relates to modified mammalian cells having reduced or eliminated expression of certain cellular proteins, CRISPR/Cas9 multiplex knockout strategies for making such cells, and methods of using such cells, e.g., in the context of cell- based therapy or as host cells in the production of a product of interest.
A method for operating a medical device includes activating a processor that receives electrical power from a battery in the medical device, measuring a temperature within a housing of the medical device, identifying a low battery voltage threshold based on the temperature, measuring a first voltage level of the battery, commencing an operation sequence after measuring the first voltage level of the battery, generating a plurality of voltage comparisons between a reference voltage level and a voltage level delivered from the battery during the operation sequence, and generating, an output indicating a low battery condition if at least one of the first voltage level of the battery is less than the low battery voltage threshold and above a predetermined minimum operating voltage threshold, or at least one voltage comparison indicating the voltage level of the battery is less than the reference voltage level during the operation sequence.
G01R 31/3835 - Arrangements for monitoring battery or accumulator variables, e.g. SoC involving only voltage measurements
G01R 31/374 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC] with means for correcting the measurement for temperature or ageing
patents
